文献速递主动脉疾病

成人主动脉缩窄患者胸主动脉腔内修复术的结局

Outcomes of thoracic endovascular aortic repair in adult coarctation patients.
PubMed 文献 · J Vasc Surg · 2017-09-22

本研究回顾性分析21例因原发性或既往开放修复术后晚期后遗症接受TEVAR的成人主动脉缩窄患者,技术成功率100%,无30天死亡或截瘫,2例术后非致残性卒中;缩窄段主动脉直径显著增加,出院收缩压显著降低,1年免于再干预率78%±9%,1年和3年生存率95%±5%。

要点

  • TEVAR治疗成人主动脉缩窄技术成功率高,无30天死亡或截瘫。
  • 支架可有效扩张缩窄段,术后收缩压显著下降。
  • 术后需关注II型内漏及再干预,1年免于再干预率78%±9%。

核心结论

  • 成人主动脉缩窄患者可安全接受TEVAR治疗,支架可成功扩张缩窄环。
  • 需更多患者和更长随访以进一步明确TEVAR在成人主动脉缩窄管理中的作用。

研究设计与样本

  • 回顾性分析所有因原发性主动脉缩窄或既往开放修复术后晚期后遗症接受TEVAR的患者。
  • 共纳入21例患者,中位年龄46岁(范围33-71岁),67%为男性(n=14)。
  • 记录人口学、合并症、手术相关变量、术后结局和再干预,并完成移植物形态的CT中心线评估。
  • 生存和再干预采用寿命表分析估计。

主要发现

  • 技术成功率为100%(95%CI 84%-100%)。
  • 无30天死亡或截瘫事件,2例(10%)发生术后非致残性卒中。
  • 在可获取CT影像的原发或复发性缩窄患者中(9例中的8例),支架近端和远端达到名义支架直径(与目标最终支架直径差范围-0.4至-1.2 mm)。

关键数值与推荐

  • 共检出3例内漏,均为与左锁骨下动脉(n=2)或迷走锁骨下动脉(n=1)相关的II型内漏。
  • 4例(19%)接受再干预,中位时间7个月(范围2-12个月),其中3例为锁骨下动脉栓塞,1例为主动脉根部置换。
  • 1年免于再干预率为78%±9%(95%CI 42%-92%)。
  • 1年和3年生存率均为95%±5%(95%CI 71%-99%)。
  • 1例晚期死亡与既存先天性心脏病并发症相关。

临床怎么用

  • TEVAR可作为成人主动脉缩窄(原发或开放修复术后晚期后遗症)的治疗选择。
  • 术后应监测内漏(尤其II型)和再干预需求,并关注血压改善情况。

局限性

  • 样本量小(21例),随访时间较短(中位8个月)。
  • 原文指出需要更多患者和更长随访以进一步明确TEVAR的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic coarctation (AC) is most commonly identified in pediatric patients; however, adults can present with late sequelae of untreated coarctation or complications of prior open repair. To date, there are limited data about the role of thoracic endovascular aortic repair (TEVAR) in this group of patients. The purpose of this analysis was to describe our experience with management of adult coarctation patients using TEVAR. METHODS: All TEVAR patients treated for primary coarctation or late sequelae of previous open repair (eg, pseudoaneurysm, recurrent coarctation or anastomotic stenosis related to index open coarctation repair) were reviewed. Demographics, comorbidities, procedure-related variables, postoperative outcomes, and reintervention were recorded. Computed tomography centerline assessments of endograft morphology were completed to delineate stent anatomy at the coarctation site. Survival and reintervention were estimated using life-table analysis. RESULTS: A total of 21 patients were identified (median age, 46 years [range, 33-71 years]; 67% male [n = 14]). Nine patients (43%) were treated for symptomatic primary (n = 6) or recurrent (n = 3) coarctation. Other indications included degenerative thoracic aneurysm (n = 6), pseudoaneurysm (n = 4), and dissection (n = 2). Technical success was 100% (95% confidence interval [CI], 84%-100%). No 30-day mortality or paraplegia events occurred; however, two patients (10%) experienced postoperative nondisabling stroke. In primary or recurrent coarctation patients with available computed tomography imaging (n = 8 of 9), nominal stent graft diameters were achieved proximal and distal to the coarctation (range, -0.4 to -1.2 mm of desired final stent diameter). Specific to the coarctation site, there was a significant increase in aortic diameter after TEVAR (before stenting, 11.5 [95% CI, 6.8-12.3] mm; after stenting, 15 [95% CI, 13.7-15.7] mm; P = .004). Concurrently, systolic arterial blood pressure at time of discharge was significantly lower (before stenting: 147 mm Hg; 95% CI, 137-157 mm Hg; after stenting: 124 mm Hg; 95% CI, 118-134 mm Hg; P = .02). For all patients, median clinical follow-up time was 8 months (interquartile range, 3-13 months; range, 1-106 months). Three endoleaks were detected, all of which were type II related to left (n = 2) or aberrant (n = 1) subclavian arteries. Four patients (19%) underwent reintervention (median time, 7 months; range, 2-12 months), with three of four being subclavian artery embolization; one was an aortic root replacement for ascending aneurysm with bicuspid aortic valve. One-year freedom from reintervention was 78% ± 9% (95% CI, 42%-92%). The 1- and 3-year survival was 95% ± 5% (95% CI, 71%-99%). One late death was related to complications from pre-existing congenital heart disease. CONCLUSIONS: Adult AC patients can be treated safely with TEVAR, and the annular constriction of an AC can be successfully dilated by the stent graft. Given these findings, a greater number of patients with longer term follow-up is warranted to further define the role of TEVAR in the management of adult AC patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lala S, Scali ST, Feezor RJ, et al. Outcomes of thoracic endovascular aortic repair in adult coarctation patients. J Vasc Surg. 2017. PMID: 28947226. doi:10.1016/j.jvs.2017.06.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。